NZ601325A - Compositions and methods for treating glioblastoma gbm - Google Patents
Compositions and methods for treating glioblastoma gbmInfo
- Publication number
- NZ601325A NZ601325A NZ601325A NZ60132511A NZ601325A NZ 601325 A NZ601325 A NZ 601325A NZ 601325 A NZ601325 A NZ 601325A NZ 60132511 A NZ60132511 A NZ 60132511A NZ 601325 A NZ601325 A NZ 601325A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- methods
- treating glioblastoma
- gbm
- glioblastoma gbm
- Prior art date
Links
- 208000005017 glioblastoma Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000013603 viral vector Substances 0.000 abstract 2
- 206010018338 Glioma Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 208000029824 high grade glioma Diseases 0.000 abstract 1
- 201000011614 malignant glioma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28222810P | 2010-01-05 | 2010-01-05 | |
| US28224810P | 2010-01-07 | 2010-01-07 | |
| PCT/IL2011/000009 WO2011083466A1 (en) | 2010-01-05 | 2011-01-05 | Compositions and methods for treating glioblastoma gbm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601325A true NZ601325A (en) | 2014-09-26 |
Family
ID=44305240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601325A NZ601325A (en) | 2010-01-05 | 2011-01-05 | Compositions and methods for treating glioblastoma gbm |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130209450A1 (enExample) |
| EP (1) | EP2521777B1 (enExample) |
| JP (2) | JP6151515B2 (enExample) |
| KR (1) | KR101810257B1 (enExample) |
| AU (1) | AU2011204407B2 (enExample) |
| CA (1) | CA2786377C (enExample) |
| MX (1) | MX338931B (enExample) |
| NZ (1) | NZ601325A (enExample) |
| SG (2) | SG10201500048SA (enExample) |
| WO (1) | WO2011083466A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| CN101570764A (zh) | 2001-10-19 | 2009-11-04 | 脉管生物生长有限公司 | 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法 |
| AU2007280017B2 (en) | 2006-07-31 | 2012-04-12 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| AU2009312355C1 (en) | 2008-11-06 | 2016-02-18 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| NZ601325A (en) | 2010-01-05 | 2014-09-26 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
| SG10201500013SA (en) | 2010-01-05 | 2015-03-30 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| NZ707336A (en) | 2012-10-17 | 2019-01-25 | Vascular Biogenics Ltd | Treatment methods using adenovirus |
| ES2774964T3 (es) | 2013-02-04 | 2020-07-23 | Vascular Biogenics Ltd | Métodos para inducir la capacidad de respuesta a un agente antiangiogénico |
| WO2015048468A1 (en) | 2013-09-27 | 2015-04-02 | Mevion Medical Systems, Inc. | Particle beam scanning |
| US9962560B2 (en) | 2013-12-20 | 2018-05-08 | Mevion Medical Systems, Inc. | Collimator and energy degrader |
| US10675487B2 (en) | 2013-12-20 | 2020-06-09 | Mevion Medical Systems, Inc. | Energy degrader enabling high-speed energy switching |
| US9661736B2 (en) | 2014-02-20 | 2017-05-23 | Mevion Medical Systems, Inc. | Scanning system for a particle therapy system |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| ES2855299T3 (es) | 2014-11-26 | 2021-09-23 | Vascular Biogenics Ltd | Lípidos oxidados y tratamiento o prevención de la fibrosis |
| US10786689B2 (en) | 2015-11-10 | 2020-09-29 | Mevion Medical Systems, Inc. | Adaptive aperture |
| US20170273926A1 (en) * | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| CN109803723B (zh) | 2016-07-08 | 2021-05-14 | 迈胜医疗设备有限公司 | 一种粒子疗法系统 |
| NZ752894A (en) | 2016-10-06 | 2023-05-26 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
| US11103730B2 (en) | 2017-02-23 | 2021-08-31 | Mevion Medical Systems, Inc. | Automated treatment in particle therapy |
| EP3645111B1 (en) | 2017-06-30 | 2025-04-23 | Mevion Medical Systems, Inc. | Configurable collimator controlled using linear motors |
| WO2019077593A1 (en) | 2017-10-20 | 2019-04-25 | Vascular Biogenics Ltd. | DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT |
| US11291861B2 (en) | 2019-03-08 | 2022-04-05 | Mevion Medical Systems, Inc. | Delivery of radiation by column and generating a treatment plan therefor |
| KR20210139329A (ko) * | 2019-03-13 | 2021-11-22 | 바스큘라 바이오제닉스 리미티드 | 항종양 요법의 방법 |
| WO2020208612A1 (en) | 2019-04-12 | 2020-10-15 | Vascular Biogenics Ltd. | Methods of anti-tumor therapy |
| US20220370716A1 (en) * | 2021-05-19 | 2022-11-24 | Alcyone Therapeutics, Inc | Fluid delivery systems and methods of treatment |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4492826B2 (ja) | 1996-11-20 | 2010-06-30 | イントロジェン セラピューティクス，インコーポレイテッド | アデノウイルスベクターの産生および精製のための改良された方法 |
| US6204055B1 (en) * | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| IL130608A0 (en) | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
| US6867022B1 (en) | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
| US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US7067649B2 (en) | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| ES2425321T3 (es) | 2000-11-17 | 2013-10-14 | Vascular Biogenics Ltd. | Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos |
| KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| CN101570764A (zh) | 2001-10-19 | 2009-11-04 | 脉管生物生长有限公司 | 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法 |
| US20080063656A1 (en) | 2004-08-09 | 2008-03-13 | Emini Emilio A | Adenoviral Vector Compositions |
| WO2006079176A1 (en) | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| TWI421078B (zh) | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | 關卡激酶抑制劑及其用途 |
| AU2007280017B2 (en) | 2006-07-31 | 2012-04-12 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| SG10201500013SA (en) | 2010-01-05 | 2015-03-30 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| NZ601325A (en) | 2010-01-05 | 2014-09-26 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
| SG10201500015TA (en) | 2010-01-12 | 2015-02-27 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
| NZ707336A (en) | 2012-10-17 | 2019-01-25 | Vascular Biogenics Ltd | Treatment methods using adenovirus |
-
2011
- 2011-01-05 NZ NZ601325A patent/NZ601325A/en not_active IP Right Cessation
- 2011-01-05 US US13/520,452 patent/US20130209450A1/en not_active Abandoned
- 2011-01-05 JP JP2012547587A patent/JP6151515B2/ja not_active Expired - Fee Related
- 2011-01-05 SG SG10201500048SA patent/SG10201500048SA/en unknown
- 2011-01-05 CA CA2786377A patent/CA2786377C/en active Active
- 2011-01-05 WO PCT/IL2011/000009 patent/WO2011083466A1/en not_active Ceased
- 2011-01-05 MX MX2012007850A patent/MX338931B/es active IP Right Grant
- 2011-01-05 AU AU2011204407A patent/AU2011204407B2/en not_active Ceased
- 2011-01-05 EP EP11731735.4A patent/EP2521777B1/en active Active
- 2011-01-05 SG SG2012049573A patent/SG182366A1/en unknown
- 2011-01-05 KR KR1020127020567A patent/KR101810257B1/ko not_active Expired - Fee Related
-
2013
- 2013-03-14 US US13/826,303 patent/US10369196B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001588A patent/JP2016128440A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2786377C (en) | 2018-02-27 |
| US20130209450A1 (en) | 2013-08-15 |
| MX2012007850A (es) | 2012-12-05 |
| AU2011204407A1 (en) | 2012-08-09 |
| CA2786377A1 (en) | 2011-07-14 |
| JP6151515B2 (ja) | 2017-06-21 |
| JP2013516456A (ja) | 2013-05-13 |
| SG182366A1 (en) | 2012-08-30 |
| MX338931B (es) | 2016-05-06 |
| EP2521777A1 (en) | 2012-11-14 |
| EP2521777B1 (en) | 2016-12-28 |
| WO2011083466A1 (en) | 2011-07-14 |
| KR20120120942A (ko) | 2012-11-02 |
| US20130303595A1 (en) | 2013-11-14 |
| AU2011204407B2 (en) | 2015-05-07 |
| JP2016128440A (ja) | 2016-07-14 |
| US10369196B2 (en) | 2019-08-06 |
| KR101810257B1 (ko) | 2017-12-18 |
| SG10201500048SA (en) | 2015-03-30 |
| EP2521777A4 (en) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601325A (en) | Compositions and methods for treating glioblastoma gbm | |
| GB201106750D0 (en) | Novel compounds | |
| PH12015502087B1 (en) | Newcastle disease viruses and uses thereof | |
| EP4582090A3 (en) | Composition comprising pegylated arginine deiminase | |
| MX355632B (es) | Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres. | |
| IN2012DN02046A (enExample) | ||
| SG10201903119QA (en) | Polypeptide vaccine | |
| EA201490559A1 (ru) | Композиция для лечения свища | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| IN2014DN06104A (enExample) | ||
| WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
| PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
| MX2024008826A (es) | Composicion para la estimulacion ovarica controlada. | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| PH12015501088A1 (en) | Dimeric compounds | |
| UA114417C2 (uk) | Інгібітори iap | |
| PH12013501205A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. | |
| MX2013004906A (es) | Nuevos inhibidores especificos de la proteasa ns3 de hcv. | |
| MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
| TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| MX2014001736A (es) | Inhibicion de angiogenesis en tumores refractarios. | |
| MX348758B (es) | Derivados de sanglifehrina y metodos para su produccion. | |
| MX2013003903A (es) | Nuevos tratamientos de infeccion por el virus de hepatitis c. | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 JAN 2018 BY DENNEMEYER + CO Effective date: 20150410 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2019 BY DENNEMEYER + CO Effective date: 20171216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2020 BY DENNEMEYER + CO Effective date: 20181220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2021 BY DENNEMEYER + CO Effective date: 20191220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2022 BY DENNEMEYER + CO Effective date: 20201228 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2023 BY DENNEMEYER + CO Effective date: 20211228 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2024 BY MS. PETRA OLK Effective date: 20221228 |
|
| LAPS | Patent lapsed |